Drug General Information
Drug ID	D04HQC
Former ID	DIB001078
Drug Name	SB-9200
Indication	HBV infection [ICD9: 070.2-070.3; ICD10:B16, B18.0, B18.1]		Phase 1	[524226]
Company	Spring bank pharmaceuticals
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Retinoic acid-inducible gene-1 (RIG-1)	Target Info	Modulator
	Pattern recognition receptor NOD2	Target Info	Modulator
KEGG Pathway	NF-kappa B signaling pathway
	RIG-I-like receptor signaling pathway
	Cytosolic DNA-sensing pathway
	Hepatitis C
	Hepatitis B
	Measles
	Influenza A
	Herpes simplex infection
	Epstein-Barr virus infectionhsa04621:NOD-like receptor signaling pathway
	TNF signaling pathway
	Shigellosis
	Tuberculosis
	Inflammatory bowel disease (IBD)
Pathway Interaction Database	Canonical NF-kappaB pathway
Reactome	ISG15 antiviral mechanism
	TRAF3-dependent IRF activation pathway
	TRAF6 mediated IRF7 activation
	TRAF6 mediated NF-kB activation
	NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
	Negative regulators of RIG-I/MDA5 signalingR-HSA-168638:NOD1/2 Signaling Pathway
	TAK1 activates NFkB by phosphorylation and activation of IKKs complex
	Interleukin-1 signaling
	activated TAK1 mediates p38 MAPK activation
	JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
WikiPathways	RIG-I/MDA5 mediated induction of IFN-alpha/beta pathwaysWP2792:MAP kinase activation in TLR cascade
	Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
	TAK1 activates NFkB by phosphorylation and activation of IKKs complex
	Interleukin-1 signaling
	NOD pathway
References
Ref 524226	ClinicalTrials.gov (NCT01803308) A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naive Adults With Chronic Hepatitis C Infection. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.